Back to Stocks

AMWL

American Well Corp
7 filings tracked
healthcarecloud computingSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Amwell is executing a decisive pivot from aggressive growth toward disciplined, platform-driven profitability. While headline revenue saw a year-over-year decline, the company successfully slashed total operating expenses by 26%, compressing its operating loss by 43%.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The narrative of a disciplined pivot masks a deteriorating core business where revenue fell 18% year-over-year.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every AMWL filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company in a race against time to align its cost structure with a shrinking revenue profile. Amwell has successfully reduced its cash burn and operating losses through aggressive austerity, but the top-line contraction and deteriorating cash conversion rates remain significant headwinds. The shift toward a 'hybrid care' platform is a strategic necessity, but the immediate financial impact is a mix of leaner operations and declining sales. Investors are left weighing a debt-free balance sheet and a reduced loss profile against the risks of extreme customer concentration and a struggling subscription model. The next twelve months will be critical, as the company must prove it can stabilize its revenue and convert its remaining performance obligations into cash without further eroding its market position or requiring additional equity financing.

Selected Quarter

Core Takeaway

Amwell is aggressively cutting costs to survive a period of declining revenues and high client concentration.

Investor Lens

The trade-off is between the immediate benefit of a leaner cost structure and the long-term risk of a shrinking, concentrated revenue base.

Watch Next

Conversion of the $106.3M remaining performance obligations into recognized revenue over the next 12 months.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.03Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 5

Revenue declined 18% year-over-year to $54.9 million.

earnings miss
70%
bullishMay 5

Operating expenses reduced by 26% through aggressive headcount and asset cuts.

margin expansion
60%
neutralMay 5

Company maintains a high cash balance but continues to operate at a net loss.

dilution risk
30%
bearishMay 5

Revenue declined 18% year-over-year to $54.9 million.

earnings miss
70%
bullishMay 5

Operating expenses reduced by 26% through aggressive headcount and asset cuts.

margin expansion
60%
neutralMay 5

Company maintains a high cash balance but continues to operate at a net loss.

dilution risk
30%
bearishMay 5

Revenue declined 18% year-over-year to $54.9 million.

earnings miss
70%
bullishMay 5

Operating expenses reduced by 26% through aggressive headcount and asset cuts.

margin expansion
60%
neutralMay 5

Company maintains a high cash balance but continues to operate at a net loss.

dilution risk
30%
bearishMay 5

Revenue declined 18% year-over-year to $54.9 million.

earnings miss
70%
bullishMay 5

Operating expenses reduced by 26% through aggressive headcount and asset cuts.

margin expansion
60%
neutralMay 5

Company maintains a high cash balance but continues to operate at a net loss.

dilution risk
30%
bearishMay 5

Revenue declined 18% year-over-year to $54.9 million.

earnings miss
70%
bullishMay 5

Operating expenses reduced by 26% through aggressive headcount and asset cuts.

margin expansion
60%
neutralMay 5

Company maintains a high cash balance but continues to operate at a net loss.

dilution risk
30%
bearishMay 5

Revenue declined 18% year-over-year to $54.9 million.

earnings miss
70%
bullishMay 5

Operating expenses reduced by 26% through aggressive headcount and asset cuts.

margin expansion
60%
neutralMay 5

Company maintains a high cash balance but continues to operate at a net loss.

dilution risk
30%
bearishMay 5

Revenue declined 18% year-over-year to $54.9 million.

earnings miss
70%
bullishMay 5

Operating expenses reduced by 26% through aggressive headcount and asset cuts.

margin expansion
60%
neutralMay 5

Company maintains a high cash balance but continues to operate at a net loss.

dilution risk
30%

Filing History

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing presents a company in a race against time to align its cost structure with a shrinking revenue profile. Amwell has successfully reduced its cash burn and operating losses through aggressive austerity, but the top-line contraction and deteriorating cash conversion rates remain significant headwinds. The shift toward a 'hybrid care' platform is a strategic necessity, but the immediate financial impact is a mix of leaner operations and declining sales. Investors are left weighing a debt-free balance sheet and a reduced loss profile against the risks of extreme customer concentration and a struggling subscription model. The next twelve months will be critical, as the company must prove it can stabilize its revenue and convert its remaining performance obligations into cash without further eroding its market position or requiring additional equity financing.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.